Non-invasive quantification of the beta cell mass by SPECT with ¹¹¹In-labelled exendin.

Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report. J Clin Endocrinol Metab (2014) 1.15

(111)In-exendin uptake in the pancreas correlates with the β-cell mass and not with the α-cell mass. Diabetes (2014) 0.84

Inside the pancreas: progress and challenges of human beta cell mass quantification. Diabetologia (2014) 0.82

Targeting GLP-1 receptors for repeated magnetic resonance imaging differentiates graded losses of pancreatic beta cells in mice. Diabetologia (2014) 0.82

A 3D map of the islet routes throughout the healthy human pancreas. Sci Rep (2015) 0.82

Combined Optical Coherence and Fluorescence Microscopy to assess dynamics and specificity of pancreatic beta-cell tracers. Sci Rep (2015) 0.81

Graft revascularization is essential for non-invasive monitoring of transplanted islets with radiolabeled exendin. Sci Rep (2015) 0.80

Automated assessment of β-cell area and density per islet and patient using TMEM27 and BACE2 immunofluorescence staining in human pancreatic β-cells. PLoS One (2014) 0.77

Evaluation of ¹¹¹in-labelled exendin-4 derivatives containing different meprin β-specific cleavable linkers. PLoS One (2015) 0.77

Cross-sectional and Test-Retest Characterization of PET with [(18)F]FP-(+)-DTBZ for β Cell Mass Estimates in Diabetes. Mol Imaging Biol (2015) 0.77

Targets and probes for non-invasive imaging of β-cells. Eur J Nucl Med Mol Imaging (2016) 0.75

Deletion of β-Arrestin2 in mice limited pancreatic beta-cell expansion under metabolic stress through activation of JNK pathway. Mol Med (2016) 0.75

Low kidney uptake of GLP-1R-targeting, beta cell-specific PET tracer, (18)F-labeled [Nle(14),Lys(40)]exendin-4 analog, shows promise for clinical imaging. EJNMMI Res (2016) 0.75

Whole organ and islet of Langerhans dosimetry for calculation of absorbed doses resulting from imaging with radiolabeled exendin. Sci Rep (2017) 0.75

Strain Differences Determine the Suitability of Animal Models for Noninvasive In Vivo Beta Cell Mass Determination with Radiolabeled Exendin. Mol Imaging Biol (2016) 0.75

SPECT-OPT multimodal imaging enables accurate evaluation of radiotracers for β-cell mass assessments. Sci Rep (2016) 0.75

A 3D-printed anatomical pancreas and kidney phantom for optimizing SPECT/CT reconstruction settings in beta cell imaging using (111)In-exendin. EJNMMI Phys (2016) 0.75

Strategies for clinical trials in type 1 diabetes. J Autoimmun (2016) 0.75

A Synthetic Heterobivalent Ligand Composed of Glucagon-Like Peptide 1 and Yohimbine Specifically Targets β Cells Within the Pancreas. Mol Imaging Biol (2015) 0.75

Non-invasive in vivo determination of viable islet graft volume by (111)In-exendin-3. Sci Rep (2017) 0.75

Radiomanganese PET Detects Changes in Functional β-cell Mass in Mouse Models of Diabetes. Diabetes (2017) 0.75

Human beta cell mass and function in diabetes: Recent advances in knowledge and technologies to understand disease pathogenesis. Mol Metab (2017) 0.75

FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging (2010) 7.82

Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80

Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes (2005) 5.54

T1DBase: integration and presentation of complex data for type 1 diabetes research. Nucleic Acids Res (2006) 3.25

The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging (2008) 3.24

The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab (2010) 3.11

Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci U S A (2011) 2.92

Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med (2006) 2.86

Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol (2009) 2.84

FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging (2014) 2.79

Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg (2006) 2.62

Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res (2002) 2.38

A novel method of 18F radiolabeling for PET. J Nucl Med (2009) 2.35

Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res (2003) 2.32

Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. Ann Neurol (2011) 2.30

Selective inhibition of eukaryotic translation initiation factor 2 alpha dephosphorylation potentiates fatty acid-induced endoplasmic reticulum stress and causes pancreatic beta-cell dysfunction and apoptosis. J Biol Chem (2006) 2.26

Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. Eur J Nucl Med Mol Imaging (2005) 2.26

The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. Eur J Nucl Med Mol Imaging (2013) 2.25

Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry (2006) 2.23

DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients. EMBO J (2012) 2.21

[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med (2006) 2.15

Caffeine can decrease insulin sensitivity in humans. Diabetes Care (2002) 2.14

The value of 18F-FDG PET/CT in diagnosing infectious endocarditis. Eur J Nucl Med Mol Imaging (2013) 2.13

Synthesis and comparison of 99mTc-enrofloxacin and 99mTc-ciprofloxacin. J Nucl Med (2004) 2.12

Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol (2013) 2.04

Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET. Radiology (2005) 2.02

The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines. PLoS Genet (2012) 1.88

A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine (Baltimore) (2007) 1.87

PET/CT: panacea, redundancy, or something in between? J Nucl Med (2004) 1.86

Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol (2010) 1.86

Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J Nucl Med (2009) 1.80

A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care (2011) 1.78

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med (2005) 1.78

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer (2010) 1.76

18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. J Nucl Med (2006) 1.75

Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med (2010) 1.71

Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos (2006) 1.71

18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. J Nucl Med (2013) 1.69

Short mucin 6 alleles are associated with H pylori infection. World J Gastroenterol (2006) 1.67

Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions. Circ Res (2012) 1.67

Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med (2010) 1.67

Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging (2006) 1.66

Optimal dose of 18F-FDG required for whole-body PET using an LSO PET camera. Eur J Nucl Med Mol Imaging (2003) 1.63

Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis. J Nucl Med (2006) 1.61

99mTc-labeled interleukin 8 for the scintigraphic detection of infection and inflammation: first clinical evaluation. J Nucl Med (2007) 1.61

Anticancer activity of targeted proapoptotic peptides. J Nucl Med (2006) 1.59

Sympathoinhibition by atorvastatin in hypertensive patients. Circ J (2010) 1.58

Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models. J Nucl Med (2005) 1.57

Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med (2003) 1.56

Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med (2003) 1.56

Detailed transcriptome atlas of the pancreatic beta cell. BMC Med Genomics (2009) 1.55

Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm (2002) 1.55

Restoration of the unfolded protein response in pancreatic β cells protects mice against type 1 diabetes. Sci Transl Med (2013) 1.55

F-18-fluorodeoxyglucose positron emission tomography combined with CT in critically ill patients with suspected infection. Intensive Care Med (2009) 1.55

PET-CT for response assessment and treatment adaptation in head and neck cancer. Lancet Oncol (2010) 1.55

Bcl-2 proteins in diabetes: mitochondrial pathways of β-cell death and dysfunction. Trends Cell Biol (2011) 1.54

Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med (2009) 1.54

Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging (2005) 1.51

Increased metabolic activity of indolent liver metastases after resection of a primary colorectal tumor. J Nucl Med (2008) 1.50

Toll-like receptor 3 and STAT-1 contribute to double-stranded RNA+ interferon-gamma-induced apoptosis in primary pancreatic beta-cells. J Biol Chem (2005) 1.50

Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer (2007) 1.50

The inflammasome puts obesity in the danger zone. Cell Metab (2012) 1.49

STAT1 is a master regulator of pancreatic {beta}-cell apoptosis and islet inflammation. J Biol Chem (2010) 1.49

Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. Eur J Nucl Med Mol Imaging (2013) 1.49

Mild endoplasmic reticulum stress augments the proinflammatory effect of IL-1β in pancreatic rat β-cells via the IRE1α/XBP1s pathway. Endocrinology (2012) 1.49

68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging (2010) 1.48

Short-term dietary restriction and fasting precondition against ischemia reperfusion injury in mice. Aging Cell (2009) 1.47

A novel facile method of labeling octreotide with (18)F-fluorine. J Nucl Med (2010) 1.47

Scintigraphic imaging of infectious foci with an 111In-LTB4 antagonist is based on in vivo labeling of granulocytes. J Nucl Med (2005) 1.47

Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med (2010) 1.46

Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D: -luciferin: effect on intensity, time kinetics and repeatability of photon emission. Eur J Nucl Med Mol Imaging (2008) 1.46